[go: up one dir, main page]

MX2016011706A - Progesterone formulations. - Google Patents

Progesterone formulations.

Info

Publication number
MX2016011706A
MX2016011706A MX2016011706A MX2016011706A MX2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A MX 2016011706 A MX2016011706 A MX 2016011706A
Authority
MX
Mexico
Prior art keywords
formulations
progesterone
progesterone formulations
amount
benefits
Prior art date
Application number
MX2016011706A
Other languages
Spanish (es)
Inventor
Sancilio Frederick
Thorsteinsson Thorsteinn
Cacace Janice
Persicaner Peter
Amadio Julia
Bernick Brian
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of MX2016011706A publication Critical patent/MX2016011706A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters, in particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
MX2016011706A 2014-03-28 2015-03-27 Progesterone formulations. MX2016011706A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972068P 2014-03-28 2014-03-28
PCT/US2015/023041 WO2015148952A1 (en) 2014-03-28 2015-03-27 Progesterone formulations

Publications (1)

Publication Number Publication Date
MX2016011706A true MX2016011706A (en) 2017-05-01

Family

ID=54196452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011706A MX2016011706A (en) 2014-03-28 2015-03-27 Progesterone formulations.

Country Status (10)

Country Link
EP (1) EP3122364A4 (en)
JP (2) JP2017509630A (en)
KR (1) KR20160137597A (en)
AR (1) AR099872A1 (en)
AU (1) AU2015237243A1 (en)
CA (1) CA2942568A1 (en)
IL (1) IL247828A0 (en)
MX (1) MX2016011706A (en)
RU (1) RU2016136666A (en)
WO (1) WO2015148952A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081726A1 (en) * 2018-10-17 2020-04-23 Stadler Sarah Sheehan Methods of treating menopausal symptoms using low dose progesterone
CN112336699A (en) * 2019-08-09 2021-02-09 南京科宁检测科技有限公司 Progesterone vaginal slow-release soft capsule and its preparation method
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2410683A1 (en) * 2000-07-24 2002-01-31 Pharmacia & Upjohn Company Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
JP2005526083A (en) * 2002-03-14 2005-09-02 ワトソン ファーマシューティカルズ， インコーポレイテッド Progesterone oral drug delivery system
ATE543489T1 (en) * 2005-05-26 2012-02-15 Teva Womens Health Inc ORAL DOSAGE FORMS CONTAINING PROGESTERONE AND METHODS OF USE AND MANUFACTURING THEREOF
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) * 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile

Also Published As

Publication number Publication date
WO2015148952A1 (en) 2015-10-01
CA2942568A1 (en) 2015-10-01
IL247828A0 (en) 2016-11-30
RU2016136666A3 (en) 2018-11-07
EP3122364A1 (en) 2017-02-01
KR20160137597A (en) 2016-11-30
JP2017509630A (en) 2017-04-06
EP3122364A4 (en) 2017-10-25
AR099872A1 (en) 2016-08-24
JP2019206540A (en) 2019-12-05
RU2016136666A (en) 2018-05-03
AU2015237243A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MY187540A (en) Compounds active towards bromodomains
EP3234107A4 (en) B cells for in vivo delivery of therapeutic agents
PH12017500163A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
PH12017500933A1 (en) Sublingual administration of riluzole
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
PH12016501841A1 (en) Immunosuppressant formulation
EP3337482A4 (en) Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
PH12017500934A1 (en) Sublingual formulation of riluzole
ZA201704026B (en) Oral octreotide administered in combination with other therapeutic agents
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016011706A (en) Progesterone formulations.
MX2021003908A (en) Long-acting polypeptides and methods of producing and administering same.
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
MA39599A (en) Dosage and administration anti-egfr therapeutics
PH12017501979A1 (en) Pharmaceutical compound
IL259712B (en) Stable dosage form of etidronate-cytarabine conjugate, and use thereof
MX2016010919A (en) 4-benzylsulfonyl-2-butenenitrile.
MA40553A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
IN2014DE00822A (en)
UA88640U (en) Use of combined drug thiocetam for correction of inflammations in oral mucosa